What the name can refer to
Cells make NAD+ all the time. They use it when they release energy from food and in reactions that help maintain and repair cells. The body also makes it out of other substances. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are precursors, meaning cells can use them as ingredients to build NAD+. The comparison of NR and NMN shows where each enters that process.
Research articles and product descriptions sometimes use the term NAD+ broadly. In an article about a trial, the methods describe what the researchers gave people, such as NR by mouth or NAD+ as an infusion. In a description of a formulation, the ingredient name refers to what went into it. The route refers to how the substance enters the body. For example, an infusion delivers fluid into a vein, and a preparation taken by mouth passes through the digestive system. A shared name in a headline can conceal both distinctions.
Where the evidence comes from
Controlled trials compare what happens with the substance being studied against a group or period used for comparison. The comparison helps separate the effect of the substance from changes that might happen over time anyway. For instance, in a controlled trial of oral NR, researchers found that the NR groups had higher whole-blood NAD+. That result describes a chemical reading after people took the ingredient by mouth.
Researchers in an NAD+ infusion pilot tracked different things. Their blood and urine samples described changes over hours and helped show when the substance and its breakdown products could be found. It was an early study of how the body handled the infusion. A trial that measured long-term symptoms would need a different design and evidence gathered over a longer period.
Three ways NAD+ comes up
Oral precursors such as NR and NMN appear in studies where the starting ingredient is taken by mouth. The human trials reviewed in 2025 offer evidence on blood readings and a smaller set of measured changes in health or ability. The results depend on the exact ingredient, the participants and the outcome the researchers chose.
A research study can test how the body handles a substance or whether it changes a particular result. The published paper describes who took part, the form that was studied and the period of observation. That information gives the result its scope. A study of one form leaves the outcomes for other forms open.
People need a prescription to get a particular NAD+ preparation through Promise Peptides (mypromise.com), which serves patients only in the United States.
How U.S. rules address compounding
FDA's overview of compounding describes how a medicine can be made to meet a particular treatment need. Section 503A covers patient-specific compounding under set conditions, including a valid prescription for an individual patient. Section 503B covers registered outsourcing facilities under a separate set of conditions. Compounded drugs are not FDA-approved. FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.
The FDA bulk-substances page explains where the ingredient itself fits into 503A. The rules consider whether the ingredient has a relevant official standard, is a component of an approved drug, or appears on the applicable bulk-substances list. In FDA's interim policy, Category 2 refers to nominated ingredients for which FDA identified significant safety concerns. FDA tracks withdrawn nominations separately.
In its October 30, 2026 notice, the U.S. Department of Health and Human Services announced a draft, nonbinding enforcement policy for state-licensed pharmacies, federal facilities and licensed physicians. It describes when the department does not intend to take action under specified 503A conditions, including a valid prescription for an individual patient. It applies to single active ingredients and names six peptides. They are BPC-157, TB-500, epitalon, KPV, MOTS-c and semax. Its scope excludes NAD+, blends and 503B outsourcing facilities. The draft grants no FDA drug approval.